Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Macugen for Adjuvant Management of TRD and Vitreous Hemorrhage in PDR
NCT01589718Phase 3Withdrawn
- Sponsor
- Greater Houston Retina Research Center
- Start
- Apr 2012
- Primary completion
- Mar 2014
- Modality
- Antisense DNA, RNA Aptamers, Small Interfering RNA (siRNA)
- Countries
- 1
01
Overview
A Phase 3 trial of pegaptanib sodium in proliferative diabetic retinopathy (PDR), sponsored by Greater Houston Retina Research Center. Planned start Apr 2012; status: withdrawn.
02
Drugs
pegaptanib sodium
03
Conditions
proliferative diabetic retinopathy (PDR)
Beyond the preview
Go deeper on NCT01589718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01589718.